Document Detail

No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-eluting stents.
MedLine Citation:
PMID:  22458576     Owner:  NLM     Status:  In-Data-Review    
Evaluation of: Stefanini GG, Kalesan B, Serruys PW et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 378(9807), 1940-1948 (2011). Biodegradable polymer-coated drug-eluting stents (DESs) represent an attractive approach to improve vascular healing after coronary intervention. The proof-of-concept chain of investigation includes preclinical safety assessment, surrogate end point clinical efficacy studies and large-scale clinical outcome studies, in which noninferiority against benchmark devices is assessed at 12 months, with adjudication of hypothesized clinical advantage at long-term follow-up. The 4-year outcome data from large-scale trials such as the LEADERS study represents a final link in this process. Data from this trial show maintenance of noninferiority and an overall improvement in the composite of death, myocardial infarction and revascularization with biodegradable polymer DESs versus durable polymer sirolimus-eluting stents that is statistically significant and perhaps also clinically important (risk ratio: 0.81; 95% CI: 0.66-1.00; p-value for superiority = 0.05). Furthermore, although reductions in the incidence of stent thrombosis with biodegradable polymer stents at 4 years did not reach statistical significance, in keeping with the hypothesized mechanism of benefit, the observed risk differences seemed to be driven by a reduction in very late events beyond 1 year after intervention. These findings are backed up by those from a pooled analysis of the three largest biodegradable polymer DES randomized trials. With the availability of high-quality biodegradable polymer devices and the phasing out of earlier generation devices, the next 5 years will see increasing uptake of this therapy in routine practice. Whether improvements in outcomes with biodegradable polymer DESs can also be demonstrated against second-generation durable polymer stents is the subject of a number of ongoing clinical trials.
Robert A Byrne; Adnan Kastrati
Related Documents :
8553306 - Randomised trial of corticosteroids in the treatment of tuberculous pleurisy.
17440006 - Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chro...
20740616 - Tocilizumab in refractory adult still's disease.
15641626 - Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharma...
8866086 - Aortobifemoral surgery induces complement activation and release of interleukin-6 but n...
3632116 - Implantation of the duromedics bileaflet cardiac valve prosthesis in 400 patients.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  10     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  429-32     Citation Subset:  IM    
Deutsches Herzzentrum, Technische Universität, Lazarettstrasse 36, 80636 Munich, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor...
Next Document:  Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era ...